Dana-Farber Cancer Institute and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center recognized for exceptional outcomes in donor stem cell transplants - Takeaways - MDSpire

Dana-Farber Cancer Institute and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center recognized for exceptional outcomes in donor stem cell transplants

Dana-Farber Cancer Institute’s adult stem cell transplant program and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center’s pediatric stem cell transplant program have once again received exceptional ratings from the Center for International Blood & Marrow Transplant Research (CIBMTR), earning a +1 performance score, the highest possible designation, on their annual center-specific survival reports.

  • By

  • December 17, 2025

  • 4 min

Share

  • 1

    Dana-Farber's adult and pediatric stem cell transplant programs received a +1 performance score from CIBMTR, indicating exceptional outcomes.

  • 2

    This marks the sixth consecutive year for the adult program and the second for the pediatric program to achieve a +1 score.

  • 3

    Dana-Farber is one of only eight centers in the U.S. identified as overperforming in the CIBMTR analysis of 176 transplant centers.

  • 4

    The pediatric program is the only dedicated program in the U.S. to exceed the expected one-year survival rate for donor stem cell transplants.

  • 5

    The CIBMTR analysis adjusts for various factors to ensure fair evaluation of each center's outcomes based on patient complexity.

Original Source(s)

Dana-Farber Cancer Institute and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center recognized for exceptional outcomes in donor stem cell transplants

  • by

  • December 17, 2025

Related Content

The clinical relevance of sole loss of chromosome Y in myeloid neoplasms

Multi-strategy feature selection and multi-model machine learning for prognostic prediction in primary gastric diffuse large B-cell lymphoma

Case Report: Atypical hepatobiliary manifestations associated with erythrocyte membrane instability in glucose transporter type 1 deficiency syndrome